Biogen's SWOT analysis: neurology giant faces pipeline hurdles, stock outlook mixed
Biogen Inc. (NASDAQ:BIIB), a leading biopharmaceutical company specializing in neurology and rare diseases, finds itself at a critical juncture as it navigates a complex landscape of opportunities and ...
The Latest: Trump wants to send immigrants who are in the US illegally to Guantanamo Bay
President Donald Trump said Wednesday that he is directing the opening of a detention center at Guantanamo Bay to hold up to ...
pharmaphorum21h
Leqembi still too pricey, says ICER in updated review
Drug cost-effectiveness organisation ICER has revised its view of Eisai’s new Alzheimer’s disease therapy Leqembi, but has concluded that the price set by the pharma group is still too high.
precisionmedicineonline23h
At Some Hospitals, Expert Panels Help Guide Anti-Amyloid Drug Decisions for Alzheimer's Patients
These boards are cropping up around the US as neurologists acclimate to a new class of drugs, but not everyone agrees such ...
The Zacks Analyst Blog Highlights Sage Therapeutics, Biogen, Cytokinetics and Akero Therapeutics
Per Sage Therapeutics, the BIIB offer significantly undervalues the company and is not in the best interest of shareholders. Biogen currently owns a 10.2% stake in SAGE, per a SEC filing by the ...
The Latest: Trump wants to send migrants who are in the U.S. illegally to Guantanamo Bay
President Donald Trump said Wednesday that he is directing the opening of a detention center at Guantanamo Bay to hold up to ...
BioPharma Dive16h
Enhertu, with new OK, set to supplant chemo in HER2-low breast cancer
The FDA clearance aids AstraZeneca and Daiichi Sankyo’s plan to position ADCs like Enhertu ahead of chemotherapy in a variety ...